EP Biocomposites Q2 FY27: Reports first loss since listing of Rs. -43.40 Lakhs
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 13 Nov 2026, 06:01 PM IST · BSE ID: 5b3fac1c-30fa-4906-ada6-ad110ec55c07
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its first financial loss since listing for the last six months, with revenue declining compared to the prior year.
🤖 AI Summary
- EP Biocomposites reported a net loss of Rs. -43.40 Lakhs for the half year ended September 30, 2026.
- Revenue from operations stood at Rs. 295.38 Lakhs for the half year ended September 30, 2026.
- This marks the first loss reported by the company since its listing, as per management commentary.
- The Board of Directors approved the unaudited financial results on November 13, 2026.
- Outstanding orders in hand are Rs. 5.74 Crores, with another Rs. 7 Crores orders expected to materialize.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Half Year Ended 30.09.2026)
295.38 Lakhs
-27.49
Total Income (Half Year Ended 30.09.2026)
304.51 Lakhs
-26.57
Profit/ (Loss) Before Tax (Half Year Ended 30.09.2026)
-45.98 Lakhs
Not comparable — limited prior period data.
Profit/ (Loss) For The Period (Half Year Ended 30.09.2026)
-43.40 Lakhs
Not comparable — limited prior period data.
Basic EPS (Half Year Ended 30.09.2026)
-2.58
Not comparable — limited prior period data.
Reserves and Surplus (as at 30.09.2026)
993.75 Lakhs
🏢 How This Affects the Company
Revenue from operations for H1 FY27 decreased to Rs. 295.38 Lakhs from Rs. 407.48 Lakhs in H1 FY26, indicating reduced sales activity. Management anticipates stronger performance in H2 FY27 based on historical trends and current orders worth Rs. 5.74 Crores.
The company recorded a net loss of Rs. -43.40 Lakhs for H1 FY27, compared to a profit of Rs. 9.04 Lakhs in H1 FY26. Reserves and surplus decreased to Rs. 993.75 Lakhs from Rs. 1,037.15 Lakhs as of March 31, 2026.
Inventories increased to Rs. 186.25 Lakhs as of September 30, 2026, from Rs. 134.25 Lakhs as of March 31, 2026. Trade receivables decreased to Rs. 1,053.83 Lakhs from Rs. 1,184.20 Lakhs in the same period.
The company's first reported loss since listing introduces a financial risk concern regarding sustained profitability. Dependency on second-half performance for overall annual profitability increases business execution risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported net loss of Rs. -43.40 Lakhs for the half year ended September 30, 2026, which impacts retained earnings. Basic EPS for the period is Rs. -2.58.
🔍
Management Signal
Management acknowledged the first loss since listing, highlighting historical second-half strength and current order book of Rs. 5.74 Crores plus Rs. 7 Crores expected.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 results — monitor if performance improves per management's H2 commentary.
Further updates on Rs. 7 Crores expected orders — check for firm order announcements.
Board meeting outcomes — any decisions related to financial performance or business strategy.
HIGH RISK
The company reported its first loss since listing and a significant decline in revenue, indicating immediate financial distress.
💡 Investor Takeaway
EP Biocomposites reported a net loss of Rs. -43.40 Lakhs for the half year ended September 30, 2026, its first loss since listing. Revenue from operations decreased to Rs. 295.38 Lakhs compared to Rs. 407.48 Lakhs in H1 FY26. Management indicated Rs. 5.74 Crores in current orders.
⚖️ Strengths & Concerns
✅ Positives
- Management noted Rs. 5.74 Crores of current orders in hand and an additional Rs. 7 Crores of orders expected to materialize.
- IPO proceeds of Rs. 580.04 Lakhs were fully utilized as of September 30, 2026, for manufacturing facilities, loan repayment, and working capital.
⚠️ Concerns
- EP Biocomposites reported its first net loss of Rs. -43.40 Lakhs for H1 FY27 since listing.
- Revenue from operations decreased to Rs. 295.38 Lakhs in H1 FY27 from Rs. 407.48 Lakhs in H1 FY26, a decline of Rs. 112.10 Lakhs.
📅 Company Track Record
EP Biocomposites Limited was incorporated in 2020. The company was recently listed via an IPO at Rs. 126 per share, aggregating to Rs. 635.00 Lakhs, with net proceeds of Rs. 580.04 Lakhs fully utilized. This half-year marks the first reported loss since listing, contrasting with a net profit after tax of Rs. 12.07 Lakhs for H1 FY26 and Rs. 136.79 Lakhs for H2 FY26.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was EP Biocomposites' net profit/loss for Q2 FY27?
EP Biocomposites reported a net loss of Rs. -43.40 Lakhs for the half year ended September 30, 2026 (Q2 FY27).
What was the revenue from operations for EP Biocomposites in Q2 FY27?
Revenue from operations for EP Biocomposites stood at Rs. 295.38 Lakhs for the half year ended September 30, 2026 (Q2 FY27).
Has EP Biocomposites reported a loss previously?
No, the management commentary states that the loss of Rs. -43.40 Lakhs for H1 FY27 is the first time the company has posted a loss since its listing.
What is the status of EP Biocomposites' order book?
The company has current orders in hand amounting to Rs. 5.74 Crores, with another Rs. 7 Crores worth of orders expected to materialize during the year.
How does H1 FY27 performance compare to H1 FY26 for EP Biocomposites?
Revenue from operations for H1 FY27 was Rs. 295.38 Lakhs, a decrease from Rs. 407.48 Lakhs in H1 FY26. The company recorded a loss of Rs. -43.40 Lakhs in H1 FY27 compared to a profit of Rs. 9.04 Lakhs in H1 FY26.
Questions based on this BSE filing only. For information purposes.